Arcus Biosciences (RCUS) Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RCUS shares.
View RCUS analyst ratings or view top-rated stocks.

9 Wall Street analysts have issued 12-month price targets for Arcus Biosciences' stock. Their RCUS share price forecasts range from $33.00 to $51.00. On average, they expect the company's share price to reach $41.44 in the next twelve months. This suggests a possible upside of 99.7% from the stock's current price.
View analysts price targets for RCUS or view top-rated stocks among Wall Street analysts.

Arcus Biosciences' stock was trading at $20.68 on January 1st, 2023. Since then, RCUS stock has increased by 0.3% and is now trading at $20.75.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our RCUS earnings forecast.

Arcus Biosciences, Inc. (NYSE:RCUS) posted its quarterly earnings results on Tuesday, May, 9th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.06) by $0.03. The firm had revenue of $25 million for the quarter, compared to analyst estimates of $22.47 million. Arcus Biosciences had a negative net margin of 233.41% and a negative trailing twelve-month return on equity of 41.22%. The firm's quarterly revenue was up 38.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.96) earnings per share.

ETFs with the largest weight of Arcus Biosciences (NYSE:RCUS) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), iShares Genomics Immunology and Healthcare ETF (IDNA), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), First Trust Innovation Leaders ETF (ILDR), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).

4 employees have rated Arcus Biosciences Chief Executive Officer Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among the company's employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics Public (HZNP), BioDelivery Sciences International (BDSI), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Agile Therapeutics (AGRX) and Advanced Micro Devices (AMD).

(RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Arcus Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.87%), State Street Corp (7.52%), FMR LLC (4.53%), Dimensional Fund Advisors LP (1.79%), Pictet Asset Management SA (1.76%) and Bank of America Corp DE (1.57%). Insiders that own company stock include Carolyn C Tang, Carolyn C Tang, Gilead Sciences Inc, Jennifer Jarrett, Juan C Jaen, Kathryn E Falberg, Robert C Goeltz II, Terry J Rosen, William Grossman and Yasunori Kaneko.
View institutional ownership trends.

Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RCUS stock can currently be purchased for approximately $20.75.

Arcus Biosciences (NYSE:RCUS) has a market capitalization of $1.52 billion and generates $112 million in revenue each year. The company earns $-267,000,000.00 in net income (profit) each year or ($3.85) on an earnings per share basis.

The company employs 366 workers across the globe.

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The official website for the company is www.arcusbio.com. The company can be reached via phone at (510) 694-6200 or via email at investorinfo@arcusbio.com.